NASDAQ: RANI - Rani Therapeutics Holdings, Inc.

Rentabilität für sechs Monate: -52.65%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Rani Therapeutics Holdings, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

weitere details
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-07-30
ISIN US7530181004
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.ranitherapeutics.com
Цена ао 1.43
Preisänderung pro Tag: +0.0813% (1.23)
Preisänderung pro Woche: +16.13% (1.06)
Preisänderung pro Monat: -18.48% (1.51)
Preisänderung über 3 Monate: -3.83% (1.28)
Preisänderung über sechs Monate: -52.65% (2.6)
Preisänderung pro Jahr: -78.63% (5.76)
Preisänderung über 3 Jahre: -90.46% (12.9)
Preisänderung seit Jahresbeginn: -5.31% (1.3)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 3.31 5
P/E 0 0
EV/EBITDA -1.65 0
Gesamt: 3.13

Effizienz

Name Bedeutung Grad
ROA, % -58.65 0
ROE, % -264.03 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.4611 10
Gesamt: 9.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 175.79 10
Rentabilität Ebitda, % 150.1 10
Rentabilität EPS, % -6.2 0
Gesamt: 6.6
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 668347 2.57
Nan Fung Group Holdings Limited 493584 1.9
United Services Automobile Association 481300 1.85
Alphabet Inc. 448492 1.72
Bank of America Corporation 114259 0.44
Geode Capital Management, LLC 113629 0.44
Blackrock Inc. 63583 0.24
Lasry, Marc 62887 0.24
Alpha Square Group S, LLC 58946 0.23
King Luther Capital Management 56129 0.22



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Mir A. Imran Executive Chairman 80k 1956 (69 Jahre)
Mr. Talat Imran CEO & Director 450k 1982 (43 Jahr)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (55 Jahre)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (65 Jahre)
Mr. Eric Groen General Counsel N/A 1971 (54 Jahr)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (48 Jahre)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

Adresse: United States, San Jose. CA, 2051 Ringwood Avenue - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.ranitherapeutics.com